HSBC/CALL/MODERNA/110/0.1/16.01.26 | Real-time BOERSE MUENCHEN 01:06:42 03/07/2024 pm IST | ||
| 3.72 EUR | +3.05% |
|
| Current month | -2.70% | ||
| 1 month | -33.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 3.72 | +3.05% |
| 02/24/02 | 3.61 | +0.56% |
| 01/24/01 | 3.59 | -3.23% |
| 28/24/28 | 3.71 | -5.60% |
| 27/24/27 | 3.93 | -3.91% |
Real-time BOERSE MUENCHEN
Last update July 03, 2024 at 01:06 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | HSBC |
| WKN | HS2FTW |
| ISIN | DE000HS2FTW9 |
| Date issued | 28/09/2023 |
| Strike | 110 $ |
| Maturity | 16/01/2026 (563 Days) |
| Parity | 10 : 1 |
| Emission price | 3.15 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.56 € |
|---|---|
| Lowest since issue | 1.33 € |
| Spread | 0.03 € |
| Spread % | 0.80% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
117.1
USD
Average target price
145.9
USD
Spread / Average Target
+24.59%
- Stock Market
- Warrants
- Warrant
